Exicure (DE:2H0)
NASDAQ:2H0
2H0 Stock Chart & Stats
€4.08
€0.00(0.00%)
At close: 4:00 PM EST
€4.08
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.48 - €8.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€17.08M
Enterprise Value€17.73M
Total Cash (Recent Filing)€2.60M
Total Debt (Recent Filing)€22.00K
Price to Earnings (P/E)―
Beta-1.51
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding6,373,937
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary SNA Platform And Focused Lead ProgramExicure’s proprietary spherical nucleic acid (SNA) platform and a clear strategic pivot to a lead program targeting stem cell mobilization create durable scientific differentiation and a focused development pathway. A concentrated program in hematologic indications aligns R&D and resources, improving long-term clarity of strategy and potential partner interest.
Zero Debt Lowers Financial RiskElimination of debt materially reduces interest and covenant risk, improving financial resilience. With no scheduled debt service, management has greater flexibility to allocate scarce cash to R&D or restructuring, extending runway relative to a leveraged peer and lowering downside risk during continued development phases.
Strengthened Leadership And Audit OversightAppointing an experienced COO and bolstering the audit committee are structural governance improvements. Stronger operational leadership and tighter audit oversight should improve reporting controls, execution discipline, and operational scaling—durable enhancements that reduce execution and compliance risk over the medium term.
Bears Say
Near-zero Revenue ProfilePersistent near-zero revenue undermines the company’s ability to self-fund development and validate commercial traction. Over multiple periods the firm has not generated sustainable sales, which increases reliance on external financing or partnerships and reduces visibility into long-term earnings potential.
Consistent Cash Burn And Negative Free Cash FlowSustained negative operating and free cash flow indicate ongoing consumption of cash to fund activities. This persistent burn constrains runway, forces recurring capital raises or asset sales, and creates structural dilution risk and operational distraction that can impede long-term program advancement.
Shrinking Equity CushionMaterial decline in shareholders’ equity diminishes the balance sheet buffer against future losses. With limited equity and ongoing deficits, the company has reduced capacity to absorb setbacks, increasing vulnerability to funding stress and weakening negotiating leverage with partners or lenders over the medium term.
Exicure News
2H0 FAQ
What was Exicure’s price range in the past 12 months?
Exicure lowest stock price was €1.48 and its highest was €8.25 in the past 12 months.
What is Exicure’s market cap?
Exicure’s market cap is €17.08M.
When is Exicure’s upcoming earnings report date?
Exicure’s upcoming earnings report date is Aug 07, 2026 which is in 64 days.
How were Exicure’s earnings last quarter?
Exicure released its earnings results on May 13, 2026. The company reported -€0.246 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.246.
Is Exicure overvalued?
According to Wall Street analysts Exicure’s price is currently Overvalued.
Does Exicure pay dividends?
Exicure does not currently pay dividends.
What is Exicure’s EPS estimate?
Exicure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure have?
Exicure has 6,373,937 shares outstanding.
What happened to Exicure’s price movement after its last earnings report?
Exicure reported an EPS of -€0.246 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.344%.
Which hedge fund is a major shareholder of Exicure?
Currently, no hedge funds are holding shares in DE:2H0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Technical Analysis
Options Prices
Currently, No data available
---